Clinical Trial Update: Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate [Phase 3]

View source ↗

Summary

Phase 3 trial comparing torcetrapib/atorvastatin versus fenofibrate shows effects on HDL-C increase and non-HDL lowering in hyperlipidemia patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia

Drugs mentioned

• FENOFIBRATE (Fenofibrate)
• Torcetrapib (torcetrapib)
• atorvastatin (atorvastatin)

Snippet

Sponsor: Pfizer | Conditions: Hyperlipidemia | Phase 3 | Status: COMPLETED